-
1
Avarept (motugivatrep) is approved in Japan for dry eye disease.
-
2
It is the first therapy in the TRPV1 antagonist class.
-
3
Estimated 20 million individuals in Japan suffer from dry eye disease.
-
4
Traditional treatments often provide inadequate relief.
-
5
Approval was supported by the Japanese 3-02 clinical trial.
-
6
Symptoms of DED include inflammation, discomfort, and reduced quality of life.
-
7
Avarept introduces a new therapeutic option in this challenging disease area.
Original Source(s)
Related Content
Why Smart Eye Surgeons Still Make Bad Growth Decisions
You’re not making poor decisions; you’re being forced to decide without clear, trustworthy data across your patient journey
by Rod Solar
April 30, 2026
-
7 min
The New Era of Postoperative Inflammation Management
What surgeons need to know about managing post-cataract inflammation
April 30, 2026
-
7 min
Optogenetic RP Therapy Gains RMAT
Ray Therapeutics secures FDA RMAT designation for its optogenetic retinitis pigmentosa therapy
April 29, 2026
-
2 min
